Buy THIOTEPA FOR INJECTION USP 15 MG THIOTEPA

Thiotepa for Injection USP 15 mg is a powder for solution used in medical treatments. This medication is administered intravenously and is manufactured by Sterimax Inc. in Canada.

Strength

15 MG

Manufacturer / TM Owner

STERIMAX INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Thiotepa for Injection USP 15 mg is generally used in medical settings for certain types of cancer treatments. It is often utilized as part of a broader treatment plan to target specific cells in the body. Patients and healthcare providers typically discuss what is Thiotepa used for based on individual medical needs.

Side Effects

Common effects of Thiotepa for Injection USP 15 mg may include nausea, vomiting, and fatigue. Some patients might experience hair loss or changes in blood cell counts. These effects can vary widely depending on the individual and the specific treatment plan.

Precautions & Warnings

Thiotepa for Injection USP 15 mg should be handled with care, as it is a potent medication. It is important to follow the instructions provided by healthcare professionals regarding storage and administration. Pregnant women and individuals with certain medical conditions should consult their healthcare provider before use.

Avoid Interactions

Thiotepa for Injection USP 15 mg may interact with other medications, including those that affect the immune system or blood cell production. It is advisable to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain supplements may also impact the effectiveness of Thiotepa.

References

Frequently Asked Questions

Thiotepa for Injection USP 15 mg is generally used in the treatment of certain types of cancer. It is often part of a broader treatment plan.

Thiotepa for Injection USP 15 mg is administered intravenously after being prepared as a solution from the powder form.

Common side effects may include nausea, vomiting, fatigue, and hair loss. These effects can vary among individuals.

Pregnant women and individuals with certain medical conditions should consult their healthcare provider before using Thiotepa for Injection USP 15 mg.

Yes, Thiotepa for Injection USP 15 mg may interact with other medications, especially those affecting the immune system or blood cell production.

Published by GNH India Pharmaceuticals Limited

Last updated: 18 May 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.